LOGO
LOGO

Quick Facts

Eli Lilly Cancels Phase 2b Study Of Bimagrumab And Tirzepatide For Strategic Reasons

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Eli Lilly and Company (LLY) has decided to halt a Phase 2b obesity study, citing strategic business considerations, according to ClinicalTrials.gov.

The study was designed to evaluate the efficacy and safety of bimagrumab, tirzepatide, and their combination in reducing body weight in adults with obesity or overweight and type 2 diabetes.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19